MorphoSys (MPSYF) Stock Price, News & Analysis

Company Overview

MorphoSys AG (OTCMKTS: MPSYF) is a Germany-based biopharmaceutical company specializing in the discovery, development and commercialization of therapeutic antibodies. Established in 1992 and headquartered in Planegg near Munich, MorphoSys leverages its proprietary HuCAL (Human Combinatorial Antibody Library) technology to generate fully human antibodies targeted at oncology and inflammatory diseases. Through this technology platform, the company aims to accelerate the identification of high-quality antibody candidates for both its internal pipeline and partner programs.

The company’s primary business activities center on advancing a diversified pipeline of antibody-based therapies. Its lead product, tafasitamab, is an Fc-enhanced CD19-directed monoclonal antibody licensed and co-commercialized with Incyte for certain types of relapsed or refractory diffuse large B-cell lymphoma. In addition, MorphoSys is developing pelabresib, a small-molecule bromodomain and extra-terminal domain (BET) inhibitor in collaboration with Constellation Pharmaceuticals, targeting myelofibrosis and other hematological malignancies. Beyond these late-stage assets, MorphoSys maintains a broad discovery portfolio in areas such as autoimmune disorders and solid tumors.

In support of its research and development programs, MorphoSys has forged multiple strategic collaborations with global pharmaceutical and biotechnology companies. These partnerships provide access to complementary expertise, co-development funding and shared commercialization rights. The company’s integrated model combines in-house capabilities—from antibody design and engineering to preclinical evaluation and manufacturing—with external alliances to optimize resource allocation and accelerate clinical progress.

MorphoSys operates on a global scale, with research facilities and manufacturing operations in Germany and strategic offices in North America to facilitate clinical development and regulatory engagement. Its management team comprises industry veterans with extensive experience in biopharmaceutical innovation, clinical development and commercial execution. By harnessing its proprietary platform and collaborative network, MorphoSys aims to deliver next-generation antibody therapies that address significant unmet medical needs.

Key Stats

• Today's Range: $73.27 to $73.27
• 50-Day Range: $73.27 to $73.27
• 52-Week Range: $71.76 to $73.27
• Volume: N/A
• Average Volume: 1,800 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MPSYF Stock Analysis - Frequently Asked Questions

How have MPSYF shares performed this year?

MorphoSys' stock was trading at $73.27 at the beginning of 2025. Since then, MPSYF shares have increased by 0.0% and is now trading at $73.27.

How do I buy shares of MorphoSys?

Shares of MPSYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MPSYF
• CIK: 1340243
• Web: www.morphosys.com
• Phone: (498) 989-9270
• Fax: N/A
• Employees: 730
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A